ArticleIndian journal of palliative care
Blood Transfusions in Patients with Advanced Cancer at the End-of-Life: Are They Really Beneficial?
Article in Indian journal of palliative care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood Transfusion in End-of-Life Cancer Care: Clinical Evidence, Patient Blood Management and Goal-Concordant Practice.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anaemia is prevalent in individuals with advanced cancer and may contribute to adversely affecting their quality of life. In palliative care (PC), red blood cell (RBC) transfusions are regularly administered to address bothersome symptoms such as fatigue and dyspnoea. However, they are not without risks and adverse effects in individuals who are often frail at the end of life. Within this context, RBC transfusion benefits and drawbacks have yet to be demonstrated. This study aimed to assess RBCs transfusion-targeted indications, practices and clinical outcomes at the end-of-life in hospitalised patients with advanced malignancy. Materials and Methods: A retrospective cohort design was used. All adults with a cancer diagnosis admitted to a PC Unit in a tertiary care centre in Saudi Arabia and who received at least one RBC transfusion between 1 January 2020 and 1 January 2024 were included in the study. Data were retrieved from their medical records (demographics, clinical and transfusion episode information) and included the Results: A total of 84 patients were included, comprising a total of 159 episodes of transfusion. Patients had a mean age of 47 years (19.4%). The most frequent location of cancer was the gastrointestinal system (34.6%). For most patients, a low haemoglobin level was the main indication for the transfusion, without precise symptoms being targeted. There was no improvement following several transfusion episodes (82.4%). A moderate negative correlation was observed between age and survival days post-transfusion. Conclusion: There is a need for further studies to better understand the benefits of RBC transfusions at the end of life. In addition, more attention is warranted to establish targeted clinical outcomes pre-transfusion rather than relying on abnormal laboratory values. Validated self-reported tools should be used to ensure the benefits of an intervention that involves such a limited and valuable resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.